Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ebixa | Memantine hydrochloride | Dementia (Alzheimer type), moderate to severe | Do not list | Complete | ||
Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Aldurazyme | Laronidase | Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie | Do not list | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
Tarceva | Erlotinib | Cancer, Lung , non-small cell | List with clinical criteria and/or conditions | Complete |